Preventive Effect of Probiotics in GDM

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-50
SponsorWomen's Hospital School Of Medicine Zhejiang University

About this trial

Gut microbiota is instrumental in the microbial and metabolic network of pregnant women, and is potentially related with gestational diabetes. Perinatal probiotic intervention contributes to improved glucose regulation during pregnancy. Our randomized, double-centered, placebo-controlled study is planned to recruit 334 pregnant women who is in high risk for gestational diabetes. They will be assumed randomly probiotic powder per day or placebo from 12-16th gestational weeks until Oral Glucose Tolerance Test (OGTT) at 24-28th gestational weeks. Perinatal outcomes about neonatal weight will be registered.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Pregnant women who meet the high-risk indicators for GDM and agree to participate in this study.

included between 12-16 gestational weeks

A woman was considered high risk when her pre-pregnancy BMI ≥ 24 kg/m², having family history of diabetes (type 1 or 2), GDM or PCOS (polycystic ovary syndrome) history, history of delivering macrosomia or stillbirth, or glucose in urine (+)

Disqualifiers

Taking probiotics or prebiotics within the past month

Have a history of allergies to the drug components or similar drugs in this study

Having long-term smoking or drinking habits

Type 1 or type 2 diabetes patients with definite diagnosis before pregnancy

Trial design

Design model

Parallel

Treatments tested in this trial

  • Probiotics

    Dietary supplement

    Probiotics powder including: Resistant dextrin, inulin, oligosaccharide, erythritol, Lactobacillus plantarum VB165, Bifidobacterium lactis VB301, Lactobacillus rhamnosus VB255, acerola cherry powder, citric acid

  • Placebo

    Dietary supplement

    placebo with similar appearance and smell but not containing probiotics

Treatment groups

334 Participants
are divided into 2 treatment groups
Group A: ProbioticsActive comparator 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

the incidence of gestational diabetes

The number of cases and incidence of gestational diabetes according to OGTT

Time frame
24-28th weeks gestation

Secondary outcomes

1

The incidence of macrosomia

macrosomia refers to a newborn weighs more than 4 kg)

Time frame
Delivery
2

Weight gain during pregnancy (kg)

Weight gain during pregnancy (kg) = Maternal weight at delivery - weight pre-pregnancy

Time frame
Delivery

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Women's Hospital School Of Medicine Zhejiang University

Lead sponsor

Quzhou Maternal and Child Health Care Hospital

Collaborator